Association of M2 Macrophages, Th2, and B Cells With Pathomechanism in Microscopic Polyangiitis Complicated by Interstitial Lung Disease.

Biomarkers Cytokines Humans Lung Diseases, Interstitial / complications Macrophages Microscopic Polyangiitis / complications
biomarkers cytokines interstitial lung disease microscopic polyangiitis pulmonary histopathology

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
08 2022
Historique:
accepted: 20 04 2022
pubmed: 3 5 2022
medline: 2 8 2022
entrez: 2 5 2022
Statut: ppublish

Résumé

To address the pathomechanism of microscopic polyangiitis (MPA) complicated by interstitial lung disease (ILD) using serum biomarker profile and pulmonary histopathology. Serum biomarkers from patients with MPA-ILD (n = 32), MPA without ILD (n = 17), and healthy controls (n = 10) were examined. Based on the biomarker profiles, principal component analysis (PCA) and cluster analysis were performed to classify patients with MPA-ILD into subgroups. Clinical characteristics and prognosis were assessed for each subgroup. Two lung biopsies were examined following H&E staining and immunostaining. T cell and macrophage polarization was skewed toward the T helper (Th) 2 cells and M2 macrophages in the MPA-ILD group relative to that in MPA without ILD group. The PCA allowed classification of the 19 biomarker profiles into 3 groups: (1) B cell- and neutrophil-related cytokines, vascular angiogenesis-related factors, extracellular matrix-producing factors; (2) Th1-driven cytokines, M1 macrophage-driven cytokines, and Th2-driven cytokines; and (3) M2 macrophage-induced and driven cytokines. The cluster analysis stratified the patients with MPA-ILD into clinically fibrotic-dominant (CFD) and clinically inflammatory-dominant (CID) groups. Notably, severe infections were significantly higher in the CFD group than in the CID group. Immunohistochemical staining demonstrated intense CXC motif chemokine ligand 13 staining in B cells and Th2 cells in the interstitium of the lungs of patients with MPA-ILD. The activation of M2 macrophages, Th2 cells, and B cells plays a key role in the pathomechanism of MPA-ILD. Classification of MPA-ILD based on serum biomarker profile would be useful in predicting the disease activity and the complications of severe infection in MPA-ILD.

Identifiants

DOI: 10.3899/jrheum.220123 PMID: 35501146
pubmed: 35501146
pii: jrheum.220123
doi: 10.3899/jrheum.220123
doi:

Substances chimiques

Biomarkers 0
Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

913-921

Informations de copyright

Copyright © 2022 by the Journal of Rheumatology.

Auteurs

Shogo Matsuda (S)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.
ORCID: 0000-0003-0023-3616

Takuya Kotani (T)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.
ORCID: 0000-0003-2190-0780

Hiroko Kuwabara (H)

H. Kuwabara, MD, PhD, Y. Hirose, MD, PhD, Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki.

Takayasu Suzuka (T)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.

Takao Kiboshi (T)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.

Yumiko Wada (Y)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.

Takaaki Ishida (T)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.

Youhei Fujiki (Y)

Y Fujiki, MD, PhD, Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan.

Hideyuki Shiba (H)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.

Kenichiro Hata (K)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.

Takeshi Shoda (T)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.

Yoshinobu Hirose (Y)

H. Kuwabara, MD, PhD, Y. Hirose, MD, PhD, Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki.

Tohru Takeuchi (T)

S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T Suzuka, MD, PhD, T. Kiboshi, MD, Y Wada, MD, PhD, T Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki.
ORCID: 0000-0002-0065-929X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Association of M2 Macrophages, Th2, and B...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Association of M2 Macrophages, Th2, and B...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Association of M2 Macrophages, Th2, and B...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Pneumopathies interstitielles › Association of M2 Macrophages, Th2, and B...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Association of M2 Macrophages, Th2, and B...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Vascularites associées aux anticorps anti-cytoplasme des neutrophiles › Polyangéite microscopique › Association of M2 Macrophages, Th2, and B...